---
title: "Alibaba Health Delivers Strong FY2026 Profit Growth and Advances Smart Healthcare Push"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286405336.md"
description: "Alibaba Health Information Technology reported a 12% revenue increase to RMB34.26 billion and a 35.2% rise in net profit to RMB1.94 billion for FY2026. Adjusted net profit grew 19.3%, supported by user growth on its healthcare platforms. The company is advancing its smart healthcare initiatives and launched a model for medical professionals. Despite positive growth, analysts rate the stock as a Sell with a price target of HK$4.60. Alibaba Health operates in the Internet healthcare sector, focusing on e-commerce and smart healthcare solutions."
datetime: "2026-05-14T10:40:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286405336.md)
  - [en](https://longbridge.com/en/news/286405336.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286405336.md)
---

# Alibaba Health Delivers Strong FY2026 Profit Growth and Advances Smart Healthcare Push

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from Alibaba Health Information Technology ( (HK:0241) ).

Alibaba Health Information Technology reported solid results for the year ended March 31, 2026, with revenue rising 12.0% to RMB34.26 billion and net profit jumping 35.2% to RMB1.94 billion. Adjusted net profit grew 19.3% to RMB2.33 billion, lifting adjusted net margin from 6.4% to 6.8%, supported by continued user growth on its Taobao and Tmall Healthcare Platform.

The company deepened its role as an online launch hub for innovative and specialty drugs and advanced the integration of localized services with Internet healthcare to build a closed-loop digital patient ecosystem. It also launched “Hydrion,” a large model tailored to doctors and medical researchers, positioning Alibaba Health to benefit from favorable Chinese policy support for Internet healthcare, medical insurance coverage of online services, and growing demand for digital tracking and smart healthcare solutions.

The most recent analyst rating on (HK:0241) stock is a Sell with a HK$4.60 price target. To see the full list of analyst forecasts on Alibaba Health Information Technology stock, see the HK:0241 Stock Forecast page.

**More about Alibaba Health Information Technology**

Alibaba Health Information Technology Limited is a Bermuda-incorporated company listed in Hong Kong that operates in the Internet healthcare and pharmaceutical e-commerce sector. The group runs the Taobao and Tmall Healthcare Platform, provides online drug retail and healthcare services, and is expanding into smart healthcare infrastructure with AI tools serving doctors and clinical professionals in China.

**Average Trading Volume:** 85,020,990

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$72.76B

For an in-depth examination of 0241 stock, go to TipRanks’ Overview page.

### Related Stocks

- [00241.HK](https://longbridge.com/en/quote/00241.HK.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)

## Related News & Research

- [Alibaba Health Declares Final Dividend for FY2026](https://longbridge.com/en/news/286406079.md)
- [DOJ Launches Criminal Probe Into Blue State Hospital](https://longbridge.com/en/news/286157785.md)
- [Distinct Healthcare Launches 2026 Share Award Scheme Funded by Existing Shares](https://longbridge.com/en/news/286330271.md)
- [Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News](https://longbridge.com/en/news/286247087.md)
- [07:03 ETPointcare Launches Coverage Advocacy Platform for 192 Million Americans](https://longbridge.com/en/news/286247622.md)